Alopecia areata therapy class competition matures
Baricitinib, ritlecitinib, and deuruxolitinib establish a competitive systemic JAK inhibitor class in severe alopecia areata.
Severe alopecia areata had no approved therapy until baricitinib in 2022. Ritlecitinib (selective JAK3-and-TEC family) and deuruxolitinib add additional approved options, follow-on systemic JAK programs are in late-stage trials, and combination strategies (systemic JAK plus topical or other agents) are in development. The category has gone from no-approved-therapy to a competitive prescribing class in three years, with the prescribing question now centred on dosing, safety profile, and severity-tier selection.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- ExplainedWhat is Sjogren disease?